Presbia to Participate in Rodman & Renshaw 19th Annual Global Investment Conference
September 07 2017 - 8:00AM
Business Wire
Presbia PLC (NASDAQ:LENS), an ophthalmic device company and
leader in near-vision restoration that has developed the Presbia
Flexivue Microlens™, a proprietary optical lens implant for
treating presbyopia, announced that Todd Cooper, President and CEO,
is scheduled to present at the Rodman & Renshaw 19th Annual
Investment Conference. The Conference will take place at the Lotte
New York Palace Hotel in New York City from September 10 to 12,
2017. Mr. Cooper will be available for one-on-one meetings.
The presentation will provide an update on the status of the
U.S. clinical trial. "Presbia plans on submitting the fourth and
final module of the IDE study to the FDA in Q4, which is a major
milestone towards approval of the Presbia Flexivue Microlens™ in
the U.S.," said Mr. Cooper.
Details of the presentation are as follows:
Date: Monday, September 11,
2017Time: 3:50 PM ETRoom: Louis (4th Floor)
Forward-Looking StatementsInformation provided and
statements contained in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements only speak as of the date of this press release and
Presbia assumes no obligation to update the information included in
this press release. Statements made in this press release that are
forward looking in nature may involve risks and uncertainties.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict.
Although Presbia believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Unless otherwise required by law, Presbia also disclaims any
obligation to update its view of any such risks or uncertainties or
to announce publicly the result of any revisions to the
forward-looking statements made in this press release.
About PresbiaPresbia PLC (NASDAQ:LENS) is an ophthalmic
device company that has developed and is currently marketing the
presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens
that is implanted in a corneal pocket created by a femtosecond
laser. The Presbia Flexivue Microlens™ has received a CE mark for
the European Economic Area, allowing the lens to be marketed in
over 30 countries across Europe. A staged pivotal U.S. clinical
trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170907005527/en/
Presbia PLCMonica Yamada,
323-860-4903monica@presbia.com
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2024 to Jul 2024
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2023 to Jul 2024